DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Recruiting

Phase 1

BI 764532 with ChemotherapyDAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Sponsor:

Boehringer Ingelheim

Code:

NCT06132113

Conditions

Neuroendocrine Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BI 764532

Carboplatin

Etoposide

Cisplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-20. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-05-12.